IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$8.70
−1.47%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.87
From 52W high−41.45%
Volume17.25M
Market cap$3.94B
P/E (TTM)—
P/S (TTM)12.1x
Div yield—
Key dataNov 4, 2026
Open
$8.87
From 52W high
−41.45%
Volume
17.25M
Market cap
$3.94B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.7x
P/E (TTM)
—
RSI (14)
33.5
MomentumView details →
1D Return
−1.47%
YTD Return
+214.14%
SummaryUpdated Jun 1, 2026
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a clinical-stage biotechnology company founded in 2007 and headquartered in San Carlos, California. Originally incorporated as Lion Biotechnologies, the company changed its name to Iovance Biotherapeutics in June 2017. The company achieved a significant milestone in February 2024 when the FDA approved its lead product <b>Amtagvi</b> (lifileucel), making it the first tumor-infiltrating lymphocyte (TIL) therapy approved for treating solid tumors. This approval transformed Iovance from a purely clinical-stage company into a commercial biotechnology enterprise focused on cancer immunotherapy.
Similar companies
Latest newsMore news →
Iovance Biotherapeutics approved inducement stock options covering 111,615 shares of its common stock for 21 new non-executive employees.19d agoIovance Biotherapeutics stock hit a 52-week high after the company raised its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.35d agoIovance Biotherapeutics raised its full year 2026 total revenue guidance to $410-$420 million, up $55 million at the midpoint from the prior $350-$370 million range, citing strong U.S. demand for Amtagvi and Proleukin.36d ago